Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Seattle Children's Hospital
Universitätsklinikum Hamburg-Eppendorf
Milton S. Hershey Medical Center
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Hackensack Meridian Health
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
Massachusetts General Hospital
Thomas Jefferson University